Login to Your Account

Spinout Obseva Targets Preterm Labor Drug

By Marie Powers and Cormac Sheridan
Staff Writers

Wednesday, September 4, 2013
Merck Serono SA spinout Obseva SA hit the ground running with a CHF32 million (US$34.7 million) Series A financing led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription